Publikationsserver
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, and iron chelators, have failed in disease-modification clinical tri...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Tuhinga |
| Reo: | Ingarihi |
| I whakaputaina: |
Philipps-Universität Marburg
2024
|
| Ngā marau: | |
| Urunga tuihono: | Kuputuhi katoa PDF |
| Tags: |
Tāpirihia he Tūtohu
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Whakarāpopototanga: | Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD).
However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs,
and iron chelators, have failed in disease-modification clinical trials. In this review, we summarize the cellular determinants
of mitochondrial dysfunction, including impairment of electron transport chain complex 1, increased oxidative
stress, disturbed mitochondrial quality control mechanisms, and cellular bioenergetic deficiency. In addition,
we outline mitochondrial pathways to neurodegeneration in the current context of PD pathogenesis, and review
past and current treatment strategies in an attempt to better understand why translational efforts thus far have been
unsuccessful. |
|---|---|
| Whakaahutanga tūemi: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
| DOI: | 10.1186/s13024-023-00676-7 |